human fc tag Search Results


recombinant human cd28 fc  (R&D Systems)
92
R&D Systems recombinant human cd28 fc
Recombinant Human Cd28 Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/pm15647361-62-16-23?v=R%26D+Systems
Average 92 stars, based on 1 article reviews
recombinant human cd28 fc - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
human bcma fc tag protein  (ACROBiosystems)
95
ACROBiosystems human bcma fc tag protein
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Human Bcma Fc Tag Protein, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/pmc11018773-261-102-107?v=ACROBiosystems
Average 95 stars, based on 1 article reviews
human bcma fc tag protein - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
adc  (R&D Systems)
93
R&D Systems adc
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Adc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/us09889206-474-4-15?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
adc - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
recombinant human ctla4fc chimera fusion protein  (R&D Systems)
94
R&D Systems recombinant human ctla4fc chimera fusion protein
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Recombinant Human Ctla4fc Chimera Fusion Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/pmc11869955__BLOODA_ADV___2024___013826___mmc1-89-6-12?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
recombinant human ctla4fc chimera fusion protein - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
human soluble b7  (R&D Systems)
92
R&D Systems human soluble b7
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Human Soluble B7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/pm38422671-65-7-18?v=R%26D+Systems
Average 92 stars, based on 1 article reviews
human soluble b7 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
biotinylated recombinant human ceacam  (R&D Systems)
93
R&D Systems biotinylated recombinant human ceacam
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Biotinylated Recombinant Human Ceacam, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/pmc12670079-172-6-16?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
biotinylated recombinant human ceacam - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
ctla  (R&D Systems)
94
R&D Systems ctla
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Ctla, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/pm14634142-60-11-17?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
ctla - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
cd40 antibody selectivity human cd40  (ACROBiosystems)
95
ACROBiosystems cd40 antibody selectivity human cd40
Fig. 4. Screening <t>CD40</t> agonist from a spike-in library using a microfluidic system. (A) RFP-positive hexameric CD40L protein–secreting cells were spiked into a 10-fold excess of BFP-positive anti-HEL antibody–secreting cells, and the mixture of cells was coencapsulated with the reporter cells. After incubation, droplets containing activated reporter cells were sorted. The proportion of droplets containing RFP- or BFP-positive cells before and after sorting was analyzed. (B) Bright-field and fluores- cence images of droplets before and after sorting.
Cd40 Antibody Selectivity Human Cd40, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/pm34117053-350-0-5?v=ACROBiosystems
Average 95 stars, based on 1 article reviews
cd40 antibody selectivity human cd40 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
human ace2 fc  (ACROBiosystems)
95
ACROBiosystems human ace2 fc
Fig. 4. Screening <t>CD40</t> agonist from a spike-in library using a microfluidic system. (A) RFP-positive hexameric CD40L protein–secreting cells were spiked into a 10-fold excess of BFP-positive anti-HEL antibody–secreting cells, and the mixture of cells was coencapsulated with the reporter cells. After incubation, droplets containing activated reporter cells were sorted. The proportion of droplets containing RFP- or BFP-positive cells before and after sorting was analyzed. (B) Bright-field and fluores- cence images of droplets before and after sorting.
Human Ace2 Fc, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/pm36085335-475-11-13?v=ACROBiosystems
Average 95 stars, based on 1 article reviews
human ace2 fc - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
ctla4 fc fusion protein  (R&D Systems)
93
R&D Systems ctla4 fc fusion protein
Fig. 4. Screening <t>CD40</t> agonist from a spike-in library using a microfluidic system. (A) RFP-positive hexameric CD40L protein–secreting cells were spiked into a 10-fold excess of BFP-positive anti-HEL antibody–secreting cells, and the mixture of cells was coencapsulated with the reporter cells. After incubation, droplets containing activated reporter cells were sorted. The proportion of droplets containing RFP- or BFP-positive cells before and after sorting was analyzed. (B) Bright-field and fluores- cence images of droplets before and after sorting.
Ctla4 Fc Fusion Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/10__1074_slash_jbc__m807618200-44-5-11?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
ctla4 fc fusion protein - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
biotinylated recombinant human il 7r alpha cd127 fc chimera avi tag  (R&D Systems)
93
R&D Systems biotinylated recombinant human il 7r alpha cd127 fc chimera avi tag
Fig. 4. Screening <t>CD40</t> agonist from a spike-in library using a microfluidic system. (A) RFP-positive hexameric CD40L protein–secreting cells were spiked into a 10-fold excess of BFP-positive anti-HEL antibody–secreting cells, and the mixture of cells was coencapsulated with the reporter cells. After incubation, droplets containing activated reporter cells were sorted. The proportion of droplets containing RFP- or BFP-positive cells before and after sorting was analyzed. (B) Bright-field and fluores- cence images of droplets before and after sorting.
Biotinylated Recombinant Human Il 7r Alpha Cd127 Fc Chimera Avi Tag, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/pmc12412469-429-0-9?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
biotinylated recombinant human il 7r alpha cd127 fc chimera avi tag - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
human fc  (R&D Systems)
93
R&D Systems human fc
Fig. 4. Screening <t>CD40</t> agonist from a spike-in library using a microfluidic system. (A) RFP-positive hexameric CD40L protein–secreting cells were spiked into a 10-fold excess of BFP-positive anti-HEL antibody–secreting cells, and the mixture of cells was coencapsulated with the reporter cells. After incubation, droplets containing activated reporter cells were sorted. The proportion of droplets containing RFP- or BFP-positive cells before and after sorting was analyzed. (B) Bright-field and fluores- cence images of droplets before and after sorting.
Human Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fc+tag/pm25231402-47-11-13?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
human fc - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human BCMA Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .

Journal: EMBO Molecular Medicine

Article Title: B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis

doi: 10.1038/s44321-024-00043-z

Figure Lengend Snippet: ( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human BCMA Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .

Article Snippet: Website links for the antibodies used in the flow cytometry are following: PerCP/Cyanine5.5 anti-human CD45 Antibody (Biolegend, 304028): https://www.biolegend.com/en-us/products/percp-cyanine5-5-anti-human-cd45-antibody-4240 ; FITC anti-human CD3 antibody (BD Biosciences, 561802): https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/fitc-mouse-anti-human-cd3.561802 ; PE/Cyanine7 anti-Human CD4 (BD Biosciences, 560649): https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/pe-cy-7-mouse-anti-human-cd4.560649 ; APC/Cyanine7 anti-Human CD8 (BD Biosciences, 557834): https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/apc-cy-7-mouse-anti-human-cd8.557834 ; APC anti-human CD19 Antibody (Biolegend, 302212): https://www.biolegend.com/en-us/products/apc-anti-human-cd19-antibody-715 ; PE anti-human CD16 Antibody (Biolegend, 302056): https://www.biolegend.com/en-us/products/pe-anti-human-cd16-antibody-569 ; PE anti-human CD56 Antibody (Biolegend, 318306): https://www.biolegend.com/en-us/products/pe-anti-human-cd56-ncam-antibody-3796 ; FITC anti-Human CD38 (BD Biosciences, 567147): https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/fitc-mouse-anti-human-cd38.567147 ; PerCP/Cyanine5.5 anti-Human CD27 (BD Biosciences, 560612): https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/percp-cy-5-5-mouse-anti-human-cd27.560612 ; PerCP anti-Human CD45 (BD Biosciences, 347464): https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/clinical-discovery-research/single-color-antibodies-ruo-gmp/percp-mouse-anti-human-cd45.347464 ; APC/Cyanine7 anti-human CD3 Antibody (Biolegend, 344818): https://www.biolegend.com/en-us/products/apc-cyanine7-anti-human-cd3-antibody-6940 ; FITC-labeled human BCMA Fc tag protein (Acrobiosystems, BCA-HF254): https://www.acrobiosystems.cn/P875-FITC-Labeled_Human_BCMA_%7C_TNFRSF17_Protein_Fc_Tag.html .

Techniques: Digital PCR, Staining, Labeling

Fig. 4. Screening CD40 agonist from a spike-in library using a microfluidic system. (A) RFP-positive hexameric CD40L protein–secreting cells were spiked into a 10-fold excess of BFP-positive anti-HEL antibody–secreting cells, and the mixture of cells was coencapsulated with the reporter cells. After incubation, droplets containing activated reporter cells were sorted. The proportion of droplets containing RFP- or BFP-positive cells before and after sorting was analyzed. (B) Bright-field and fluores- cence images of droplets before and after sorting.

Journal: Science advances

Article Title: High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics.

doi: 10.1126/sciadv.abe3839

Figure Lengend Snippet: Fig. 4. Screening CD40 agonist from a spike-in library using a microfluidic system. (A) RFP-positive hexameric CD40L protein–secreting cells were spiked into a 10-fold excess of BFP-positive anti-HEL antibody–secreting cells, and the mixture of cells was coencapsulated with the reporter cells. After incubation, droplets containing activated reporter cells were sorted. The proportion of droplets containing RFP- or BFP-positive cells before and after sorting was analyzed. (B) Bright-field and fluores- cence images of droplets before and after sorting.

Article Snippet: CD40 antibody selectivity Human CD40 (ACROBiosystems), GITR (ACROBiosystems), OX40 (ACROBiosystems), 4-1BB (ACROBiosystems), or bovine serum albumin (BSA) (Solarbio) was plated onto a microtiter plate at 4°C overnight.

Techniques: Incubation

Fig. 5. Screening CD40 agonist antibody from a monoclonal antibody library. HEK293FT cells were infected with a lentivirus antibody library and individually coen- capsulated with Jurkat/NF-B-GFP-hCD40 reporter cells and fluorescence-labeled secondary antibodies in droplets. Droplets containing reporter cells activated by anti- bodies secreted by the coencapsulated antibody–expressing cells were sorted. The sorted cells were expanded for the second round of selection, and enriched antibodies were identified by next-generation sequencing. (A) Schematic of possible time traces. (B) Proportions of different types of droplets for each round of selection were analyzed. (C) Bright-field and fluorescence images of the sorted droplets after the second round of selection. (D) Bar plot for the top 20 scFv clusters and their fre- quencies during the selection process. (E) The change in frequencies of the selected antibodies during the selection process. (F) Agonist activity of the selected antibodies was determined using the CD40 reporter cell line in the presence or absence of the cross-linking secondary antibody.

Journal: Science advances

Article Title: High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics.

doi: 10.1126/sciadv.abe3839

Figure Lengend Snippet: Fig. 5. Screening CD40 agonist antibody from a monoclonal antibody library. HEK293FT cells were infected with a lentivirus antibody library and individually coen- capsulated with Jurkat/NF-B-GFP-hCD40 reporter cells and fluorescence-labeled secondary antibodies in droplets. Droplets containing reporter cells activated by anti- bodies secreted by the coencapsulated antibody–expressing cells were sorted. The sorted cells were expanded for the second round of selection, and enriched antibodies were identified by next-generation sequencing. (A) Schematic of possible time traces. (B) Proportions of different types of droplets for each round of selection were analyzed. (C) Bright-field and fluorescence images of the sorted droplets after the second round of selection. (D) Bar plot for the top 20 scFv clusters and their fre- quencies during the selection process. (E) The change in frequencies of the selected antibodies during the selection process. (F) Agonist activity of the selected antibodies was determined using the CD40 reporter cell line in the presence or absence of the cross-linking secondary antibody.

Article Snippet: CD40 antibody selectivity Human CD40 (ACROBiosystems), GITR (ACROBiosystems), OX40 (ACROBiosystems), 4-1BB (ACROBiosystems), or bovine serum albumin (BSA) (Solarbio) was plated onto a microtiter plate at 4°C overnight.

Techniques: Infection, Fluorescence, Labeling, Expressing, Selection, Next-Generation Sequencing, Activity Assay